Navigation Links
Medivation to Present at 8th Annual Needham Life Sciences Conference
Date:6/4/2009

SAN FRANCISCO, June 4 /PRNewswire-FirstCall/ -- Medivation, Inc. (Nasdaq: MDVN) today announced that David Hung, M.D., president and chief executive officer, will present at the 8th Annual Needham Life Sciences Conference on Thursday, June 11, at 10:30 a.m. Eastern Time at the New York Palace Hotel.

Dr. Hung will provide an overview of Medivation and its clinical development programs for Dimebon for Alzheimer's and Huntington's diseases and MDV3100 for prostate cancer.

A live audio webcast of the corporate presentation will be available on the "Events and Presentations" page of the "Investor Relations" section of the Company's website at http://www.medivation.com. A replay also will be available for 30 days following the live presentation.

About Medivation

Medivation, Inc. is a biopharmaceutical company focused on the rapid development of novel small molecule drugs to treat serious diseases for which there are limited treatment options. Medivation aims to transform the treatment of these diseases and offer hope to critically ill patients and their caregivers. In September 2008, Medivation announced a global agreement with Pfizer Inc to develop and commercialize Dimebon for the treatment of Alzheimer's and Huntington's diseases. With Pfizer, the Company is conducting a broad Dimebon clinical development program that includes several Phase 3 trials assessing the efficacy and safety of Dimebon taken alone or in combination with other Alzheimer's medication in patients with mild, moderate or severe Alzheimer's disease. Further development of Dimebon in patients with Huntington's disease is also planned. In addition, a Phase 1-2 clinical trial of MDV3100 in patients with castration-resistant (also known as hormone-refractory) prostate cancer is ongoing. For more information, please visit us at http://www.medivation.com.


'/>"/>
SOURCE Medivation, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Medivation Announces Offering of 2,750,000 Shares of Common Stock
2. Medivation Announces Upcoming Presentation of New MDV3100 Data in Patients With Advanced Prostate Cancer at 45th American Society of Clinical Oncology Annual Meeting
3. Medivation to Present at the Leerink Swann Novel Cancer Therapeutics Roundtable Conference
4. Medivation Reports First Quarter 2009 Financial Results and Provides Corporate Update
5. Medivation Receives FDA Permission to Initiate Phase 3 Trial of MDV3100 in Castration-Resistant Prostate Cancer
6. Medivation Announces Fourth Quarter and Year-End 2008 Teleconference and Webcast on March 16, 2009
7. Medivation to Host Conference Call and Slide Presentation at 4:30 p.m. EST Wednesday, February 25, to Discuss New MDV3100 Efficacy and Safety Data From Trial in Castration-Resistant Prostate Cancer Patients
8. Medivation Announces Participation in Upcoming Conferences
9. Medivation Announces Participation in 27th Annual J.P. Morgan Healthcare Conference
10. Medivation Announces Participation in Upcoming Conferences
11. Medivation to Present at Cowen and Companys 28th Annual Health Care Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/20/2017)... (PRWEB) , ... February 20, 2017 , ... ... and check-in, a cloud-based self-service technology that runs on the Posiflex XT-series of ... No. 1076 during HIMSS17 in Orlando, Florida. The terminal provider Posiflex ...
(Date:2/20/2017)... ... February 20, 2017 , ... Best Doctors® and IBM ... benefit for companies that want to help members of their workforce battling cancer. ... access to Watson’s suite of oncology offerings for insights on cancer treatment options, ...
(Date:2/20/2017)... ... February 20, 2017 , ... Chuck E. Cheese’s® and Center for ... joint event at Chuck E. Cheese’s locations throughout New England, New York and New ... opportunity to experience the fun of visiting Chuck E. Cheese’s in a sensory-friendly environment. ...
(Date:2/19/2017)... Van Wert, OH (PRWEB) , ... February 19, 2017 , ... ... known as The JEMS Conference & Exposition, the event will take place February 23-25, ... Utah. Braun Industries will be in Booth #909 with three new ambulances ...
(Date:2/18/2017)... Church, VA (PRWEB) , ... ... ... Culture of Change for Devicemakers , Sponsored by Axendia, **FDAnews Free Webinar**, ... , Are manufacturers looking to reduce their regulatory burden? Pay dividends ...
Breaking Medicine News(10 mins):
(Date:2/17/2017)... 2017 According to a new market research ... Counters), Application (Cleanroom Monitoring, Contamination Monitoring of Liquids), and End User ... MarketsandMarkets, the market is expected to reach USD 330.6 Million by ... 3.7% from 2016 to 2021. Continue ... ...
(Date:2/17/2017)... Feb. 17, 2017 Theravance Biopharma, Inc. ... the "Company") today announced the presentation of positive ... orally administered pan-Janus kinase (JAK) inhibitor designed to ... Congress of the European Crohn,s and Colitis Organization ... further data from its completed Phase 1 study ...
(Date:2/17/2017)... 17, 2017 Research and Markets has announced the ... report to their offering. ... The report provides separate comprehensive analytics for the US, Canada ... Asia-Pacific , and Rest of World. Annual estimates and ... historic analysis is provided for these markets. Market data and analytics are ...
Breaking Medicine Technology: